Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep1190 | Late Breaking | ECE2022

NanoLuc® Binary Technology to explore the mechanism of action of a Magmas inhibitor

Borges de Souza Patricia , Gagliardi Irene , Ambrosio Maria Rosaria , Bondanelli Marta , Zatelli Maria Chiara

Introduction: Magmas encodes for an integral constituent of the TIM23 translocase complex located in the mitochondrial inner membrane that drives proteins from the intermembrane space into the mitochondrial matrix by functionally interacting with Tim14. We previously demonstrated that Magmas silencing is able to sensitize ACTH-secreting mouse pituitary adenoma cells to pro-apoptotic stimuli, reduce DNA synthesis, accumulate cells in G0/G1 phase with concomitant decrease in S p...

ea0090p664 | Endocrine-related Cancer | ECE2023

Mutational profiles of typical and atypical bronchial carcinoids

Gagliardi Irene , Borges de Souza Patricia , Rossi Lucrezia , Rosaria Ambrosio Maria , Chiara Zatelli Maria

Introduction: Typical and Atypical bronchial carcinoids (TBC and ABC) are rare neuroendocrine neoplasms (NEN). TBC are low grade and well-differentiated NEN often with indolent clinical behavior, slow growth, rare extra-thoracic metastases, and with a long survival following surgical resection. Conversely, ABC have often a worse prognosis with a greater tendency to metastasize and recur. A better understanding of TBC and ABC genetic background would help in evaluating prognosi...

ea0070aep603 | Pituitary and Neuroendocrinology | ECE2020

TGF-β increases caspase 3 activation and migration in bronchial carcinoids

Borges de Souza Patricia , Tagliatti Valentina , Capobianco Simonaco , Rosaria Ambrosio Maria , Chiara Zatelli Maria

Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). First-line treatment is radical removal of the primary tumour; however, management of metastatic BC is still challenging. Bronchial carcinoids (BC) may benefit from treatment with mTOR inhibitors, although response rates are moderate. TBC have shown reduced sensibility to mTOR inhibitors respect to ABC, notwithstanding its less aggressive behaviour. PI3...

ea0070ep445 | Thyroid | ECE2020

Clustering techniques for thyroid nodules malignancy inference in the era of personalized medicine

Giani Andrea , Borges de Souza Patricia , Bartoletti Stefania , Morselli Flavio , Conti Andrea , Chiara Zatelli Maria

Introduction: Thyroid nodules (TN) are common entities usually discovered during a physical exam or by chance with ultrasound (US) procedures performed for reasons different from thyroid check. The majority of nodules are benign, notwithstanding the growing incidence of thyroid cancer (TC), which increases much largely as compared to all other tumours each year and will be, presumably, the most incident malignancy in women after breast cancer. The clinical challenge relies on ...

ea0063gp87 | Thyroid Nodules and Cancer | ECE2019

Intronic RAS and PI3KCA mutations identified by Next Generation Sequencing in thyroid nodules with indeterminate cytology may associate with follicular thyroid cancer

Borges de Souza Patricia , Rossi Lucrezia , Crociara Anna , Rossi Roberta , Ambrosio Maria Rosaria , Rossi Martina , Bondanelli Marta , Lanza Giovanni , Zatelli Maria Chiara

Introduction: Accurately discern malignant from benign nodules sometimes represents a real challenge. Fine needle aspiration (FNA) biopsy, ultrasound and The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) allow for accurate diagnosis in 60–80% of all nodules. However, 10–20% of thyroid FNAs yield an indeterminate cytology (BSRTC III and IV categories). The real malignancy rate of BSRTC III category is difficult to ascertain because histopathological anal...